Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Weighted Average) (2016 - 2025)

ImmunityBio (IBRX) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $919.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 31.92% to $919.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $919.9 million, a 31.92% increase, with the full-year FY2025 number at $919.9 million, up 31.92% from a year prior.
  • Shares Outstanding (Weighted Average) was $919.9 million for Q4 2025 at ImmunityBio, down from $946.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $946.6 million in Q3 2025 to a low of $382.7 million in Q1 2021.
  • A 5-year average of $565.6 million and a median of $446.2 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 1.27% in 2021, then soared 57.06% in 2024.
  • ImmunityBio's Shares Outstanding (Weighted Average) stood at $389.2 million in 2021, then rose by 2.74% to $399.9 million in 2022, then grew by 27.19% to $508.6 million in 2023, then surged by 37.09% to $697.3 million in 2024, then skyrocketed by 31.92% to $919.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Shares Outstanding (Weighted Average) are $919.9 million (Q4 2025), $946.6 million (Q3 2025), and $870.8 million (Q2 2025).